Zogenix Inc. (NASDAQ:ZGNX) – Research analysts at Leerink Swann issued their Q3 2016 earnings estimates for shares of Zogenix in a research report issued on Tuesday. Leerink Swann analyst P. Matteis anticipates that the brokerage will earn ($0.99) per share for the quarter. Leerink Swann has a “Outperform” rating and a $17.00 price objective on the stock. Leerink Swann also issued estimates for Zogenix’s Q4 2016 earnings at ($1.12) EPS, FY2016 earnings at ($3.25) EPS, FY2017 earnings at ($3.76) EPS and FY2018 earnings at ($2.26) EPS.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.05. Zogenix had a negative net margin of 192.64% and a negative return on equity of 33.62%. The company had revenue of $2.10 million for the quarter, compared to the consensus estimate of $5.36 million. During the same quarter in the prior year, the company earned ($3.78) EPS. Zogenix’s quarterly revenue was down 71.6% on a year-over-year basis.
Several other equities analysts have also recently issued reports on ZGNX. Zacks Investment Research cut Zogenix from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. Brean Capital reiterated a “buy” rating and issued a $28.00 price objective on shares of Zogenix in a research note on Wednesday, September 21st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Zogenix presently has a consensus rating of “Buy” and a consensus price target of $20.50.
Zogenix (NASDAQ:ZGNX) opened at 10.18 on Thursday. Zogenix has a one year low of $7.33 and a one year high of $16.56. The firm’s market cap is $252.36 million. The company has a 50-day moving average of $9.66 and a 200 day moving average of $9.52.
A number of large investors have recently bought and sold shares of ZGNX. Landscape Capital Management L.L.C. acquired a new stake in Zogenix during the first quarter valued at $1,439,000. State Street Corp boosted its stake in Zogenix by 4.2% in the first quarter. State Street Corp now owns 383,552 shares of the company’s stock valued at $3,546,000 after buying an additional 15,446 shares during the last quarter. Geode Capital Management LLC boosted its stake in Zogenix by 11.7% in the first quarter. Geode Capital Management LLC now owns 153,464 shares of the company’s stock valued at $1,418,000 after buying an additional 16,093 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Zogenix by 15.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 19,892 shares of the company’s stock valued at $184,000 after buying an additional 2,671 shares during the last quarter. Finally, Opaleye Management Inc. acquired a new stake in Zogenix during the first quarter valued at $2,218,000. Hedge funds and other institutional investors own 84.91% of the company’s stock.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.